SCHEMBL5724042

SCHEMBL5724042

CS(=O)(=O)OC1CN(c2nc(C(=O)Nc3ccccc3)cs2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 5/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 3/20 0.43
L3MBTL1 Q9Y468 4/20 0.41
KMT2A Q03164 2/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
ATM Q13315 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
GAA P10253 3/20 0.40
DNM1L O00429 6/20 0.40
CHEK1 O14757 1/20 0.40
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724259 0.84 OGA (0.41) NPC1RAB9AGAAPOLBHPGD
SCHEMBL5724510 0.84 TDP1 (0.54) TDP1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5723964 0.82 OGA (0.46) L3MBTL1
SCHEMBL5723946 0.81 ACKR3 (0.43) DNM1L
SCHEMBL5723880 0.81 PARP1 (0.39) L3MBTL1POLB
SCHEMBL5724316 0.80 TDP1 (0.43) TDP1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5724092 0.80 OGA (0.44) ALDH1A1KMT2ADNM1L
SCHEMBL5724320 0.80 OGA (0.46) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL5723657 0.79 HRH3 (0.47) LMNAALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5724022 0.79 OGA (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD TDP1 3179/4885LMNA 3159/4885ALDH1A1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.